|
1
|
Jaccard A and Hermine O: A major turning
point in NK/T-cell lymphoma? Blood. 129:2342–2343. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tse E and Kwong YL: Nasal NK/T-cell
lymphoma: RT, CT, or both. Blood. 126:1400–1401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haverkos BM, Pan Z, Gru AA, Freud AG,
Rabinovitch R, Xu-Welliver M, Otto B, Barrionuevo C, Baiocchi RA,
Rochford R and Porcu P: Extranodal NK/T cell lymphoma, nasal type
(ENKTL-NT): An update on epidemiology, clinical presentation, and
natural history in north American and european cases. Curr Hematol
Malig Rep. 11:514–527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Johnson WT and Mishra A: The EZ-riding
NK/T-cell lymphoma. Blood. 134:1999–2000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Somasundaram N, Lim JQ, Ong CK and Lim ST:
Pathogenesis and biomarkers of natural killer T cell lymphoma
(NKTL). J Hematol Oncol. 12:282019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kucuk C, Jiang B, Hu X, Zhang W, Chan JKC,
Xiao W, Lack N, Alkan C, Williams JC, Avery KN, et al: Activating
mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK
cells. Nat Commun. 6:60252015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen YW, Guo T, Shen L, Wong KY, Tao Q,
Choi WWL, Au-Yeung RKH, Chan YP, Wong MLY, Tang JCO, et al:
Receptor-type tyrosine-protein phosphatase κ directly targets STAT3
activation for tumor suppression in nasal NK/T-cell lymphoma.
Blood. 125:1589–1600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kwong YL, Chan TSY, Tan D, Kim SJ, Poon
LM, Mow B, Khong PL, Loong F, Au-Yeung R, Iqbal J, et al: PD1
blockade with pembrolizumab is highly effective in relapsed or
refractory NK/T-cell lymphoma failing l-asparaginase. Blood.
129:2437–2442. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Y and Teng JS: Increased multi-drug
resistance and reduced apoptosis in osteosarcoma side population
cells are crucial factors for tumor recurrence. Exp Ther Med.
12:81–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim MC, D'Costa S, Suter S and Kim Y:
Evaluation of a side population of canine lymphoma cells using
Hoechst 33342 dye. J Vet Sci. 14:481–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moti N, Malcolm T, Hamoudi R, Mian S,
Garland G, Hook CE, Burke GAA, Wasik MA, Merkel O, Kenner L, et al:
Anaplastic large cell lymphoma-propagating cells are detectable by
side population analysis and possess an expression profile
reflective of a primitive origin. Oncogene. 34:1843–1852. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Teshima K, Nara M, Watanabe A, Ito M,
Ikeda S, Hatano Y, Oshima K, Seto M, Sawada K and Tagawa H:
Dysregulation of BMI1 and microRNA-16 collaborate to enhance an
anti- apoptotic potential in the side population of refractory
mantle cell lymphoma. Oncogene. 33:2191–2203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamazaki J, Mizukami T, Takizawa K,
Kuramitsu M, Momose H, Masumi A, Ami Y, Hasegawa H, Hall WW,
Tsujimoto H, et al: Identification of cancer stem cells in a
tax-transgenic (Tax-Tg) mouse model of adult T-cell
leukemia/lymphoma. Blood. 114:2709–2720. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zabierowski SE and Herlyn M: Learning the
ABCs of melanoma-initiating cells. Cancer Cell. 13:185–187. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Fu X, Dong M, Yang Z, Wu S, Ma M,
Li Z, Wang X, Li L, Li X, et al: Conserved cell populations in
doxorubicin- resistant human nasal natural killer/T cell lymphoma
cell line: Super multidrug resistanT cells? Cancer Cell Int.
18:1502018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mo W and Zhang JT: Human ABCG2: Structure,
function, and its role in multidrug resistance. Int J Biochem Mol
Biol. 3:1–27. 2012.PubMed/NCBI
|
|
17
|
Mao Q and Unadkat JD: Role of the breast
cancer resistance protein (BCRP/ABCG2) in drug transport-an update.
AAPS J. 17:65–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noguchi K, Katayama K and Sugimoto Y:
Human ABC transporter ABCG2/BCRP expression in chemoresistance:
Basic and clinical perspectives for molecular cancer therapeutics.
Pharmgenomics Pers Med. 7:53–64. 2014.PubMed/NCBI
|
|
19
|
Nagata H, Konno A, Kimura N, Zhang Y,
Kimura M, Demachi A, Sekine T, Yamamoto K and Shimizu N:
Characterization of novel natural killer (NK)-cell and gammadelta
T-cell lines established from primary lesions of nasal T/NK-cell
lymphomas associated with the epstein-barr virus. Blood.
97:708–713. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Zhang X, Xue W, Zhang Y, Li C, Song
Y, Mei M, Lu L, Wang Y, Zhou Z, et al: Recurrent GNAQ mutation
encoding T96S in natural killer/T cell lymphoma. Nat Commun.
10:42092019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Manska S, Octaviano R and Rossetto CC:
5-Ethynyl- 2′-deoxycytidine and 5-ethynyl-2′-deoxyuridine are
differentially incorporated in cells infected with HSV-1, HCMV, and
KSHV viruses. J Biol Chem. 295:5871–5890. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghosh S and Mukherjee S: Testicular germ
cell apoptosis and sperm defects in mice upon long-term high fat
diet feeding. J Cell Physiol. 233:6896–6909. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
To KKW, Poon DC, Wei Y, Wang F, Lin G and
Fu L: Pelitinib (EKB-569) targets the up-regulation of ABCB1 and
ABCG2 induced by hyperthermia to eradicate lung cancer. Br J
Pharmacol. 172:4089–4106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ,
Gupta P, Shukla S, Ambudkar SV, Kong D and Chen ZS: Selonsertib
(GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in
ABCB1- and ABCG2-overexpressing cancer cells. Cancer Lett.
440-441:82–93. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
To KKW, Poon DC, Wei Y, Wang F, Lin G and
Fu LW: Vatalanib sensitizes ABCB1 and ABCG2-overexpressing
multidrug resistant colon cancer cells to chemotherapy under
hypoxia. Biochem Pharmacol. 97:27–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Campbell GR, To RK and Spector SA: TREM-1
protects HIV-1-infected macrophages from apoptosis through
maintenance of mitochondrial function. mBio. 10:e02638–19. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Riedell PA and Smith SM: Double hit and
double expressors in lymphoma: Definition and treatment. Cancer.
124:4622–4632. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
de Mel S, Hue SSS, Jeyasekharan AD, Chng
WJ and Ng SB: Molecular pathogenic pathways in extranodal NK/T cell
lymphoma. J Hematol Oncol. 12:332019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hu J, Li J, Yue X, Wang J, Liu J, Sun L
and Kong D: Expression of the cancer stem cell markers ABCG2 and
OCT-4 in right-sided colon cancer predicts recurrence and poor
outcomes. Oncotarget. 8:28463–28470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Farhana L, Nangia-Makker P, Arbit E,
Shango K, Sarkar S, Mahmud H, Hadden T, Yu Y and Majumdar APN: Bile
acid: A potential inducer of colon cancer stem cells. Stem Cell Res
Ther. 7:1812016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Di Desidero T, Orlandi P, Fioravanti A,
Alì G, Cremolini C, Loupakis F, Gentile D, Banchi M, Cucchiara F,
Antoniotti C, et al: Chemotherapeutic and antiangiogenic drugs
beyond tumor progression in colon cancer: Evaluation of the effects
of switched schedules and related pharmacodynamics. Biochem
Pharmacol. 164:94–105. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hsu HH, Chen MC, Baskaran R, Lin YM, Day
CH, Lin YJ, Tu CC, Padma VV, Kuo WW and Huang CY: Oxaliplatin
resistance in colorectal cancer cells is mediated via activation of
ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol.
233:5458–5467. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao L, Ren Y, Tang H, Wang W, He Q, Sun
J, Zhou X and Wang A: Deregulation of the miR-222-ABCG2 regulatory
module in tongue squamous cell carcinoma contributes to
chemoresistance and enhanced migratory/invasive potential.
Oncotarget. 6:44538–44550. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peña-Solórzano D, Stark SA, König B,
Sierra CA and Ochoa-Puentes C: ABCG2/BCRP: Specific and nonspecific
modulators. Med Res Rev. 37:987–1050. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sugimoto R, Watanabe H, Ikegami K, Enoki
Y, Imafuku T, Sakaguchi Y, Murata M, Nishida K, Miyamura S, Ishima
Y, et al: Down-regulation of ABCG2, a urate exporter, by
parathyroid hormone enhances urate accumulation in secondary
hyperparathyroidism. Kidney Int. 91:658–670. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang XK, He JH, Xu JH, Ye S, Wang F, Zhang
H, Huang ZC, To KKW and Fu LW: Afatinib enhances the efficacy of
conventional chemotherapeutic agents by eradicating cancer
stem-like cells. Cancer Res. 74:4431–4445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang XK, To KK, Huang LY, Xu JH, Yang K,
Wang F, Huang ZC, Ye S and Fu LW: Afatinib circumvents multidrug
resistance via dually inhibiting ATP binding cassette subfamily G
member 2 in vitro and in vivo. Oncotarget. 5:11971–11985. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
van Hoppe S, Sparidans RW, Wagenaar E,
Beijnen JH and Schinkel AH: Breast cancer resistance protein
(BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and
restrict its oral availability and brain accumulation. Pharmacol
Res. 120:43–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu J, Zhang X, Wang F, Wang X, Yang K, Xu
M, To KKW, Li Q and Fu L: Effect of ceritinib (LDK378) on
enhancement of chemotherapeutic agents in ABCB1 and ABCG2
overexpressing cells in vitro and in vivo. Oncotarget.
6:44643–44659. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang W, Ding W, Chen Y, Feng M, Ouyang Y,
Yu Y and He Z: Up-regulation of breast cancer resistance protein
plays a role in HER2-mediated chemoresistance through PI3K/Akt and
nuclear factor-kappa B signaling pathways in MCF7 breast cancer
cells. Acta Biochim Biophys Sin (Shanghai). 43:647–653. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gong W, Wang Z, Wan Y, Shi L and Zhou Y:
Downregulation of ABCG2 protein inhibits migration and invasion in
U251 glioma stem cells. Neuroreport. 25:625–632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nie S, Huang Y, Shi M, Qian X, Li H, Peng
C, Kong B, Zou X and Shen S: Protective role of ABCG2 against
oxidative stress in colorectal cancer and its potential underlying
mechanism. Oncology Rep. 40:2137–2146. 2018.
|
|
44
|
Wang H, Wang X, Hu R, Yang W, Liao A, Zhao
C, Zhang J and Liu Z: Methylation of SFRP5 is related to multidrug
resistance in leukemia cells. Cancer Gene Ther. 21:83–89. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang GL, Song W, Zhou P, Fu QR, Lin C,
Chen QX and Shen DY: Oncogenic retinoic acid receptor γ knockdown
reverses multi-drug resistance of human colorectal cancer via
Wnt/β-catenin pathway. Cell Cycle. 16:685–692. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luo K, Gu X, Liu J, Zeng G, Peng L, Huang
H, Jiang M, Yang P, Li M, Yang Y, et al: Inhibition of disheveled-2
resensitizes cisplatin-resistant lung cancer cells through
down-regulating Wnt/β -catenin signaling. Exp Cell Res.
347:105–113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhou H, Lin C, Zhang Y, Zhang X, Zhang C,
Zhang P, Xie X and Ren Z: miR-506 enhances the sensitivity of human
colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp
expression. Cell Prolif. 50:e123412017. View Article : Google Scholar
|
|
48
|
Shen DY, Zhang W, Zeng X and Liu CQ:
Inhibition of Wnt/β -catenin signaling downregulates P-glycoprotein
and reverses multi-drug resistance of cholangiocarcinoma. Cancer
Sci. 104:1303–1308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang H, Jing X, Wu X, Hu J, Zhang X, Wang
X, Su P, Li W and Zhou G: Suppression of multidrug resistance by
rosiglitazone treatment in human ovarian cancer cells through
downregulation of FZD1 and MDR1 genes. Anticancer Drugs.
26:706–715. 2015. View Article : Google Scholar : PubMed/NCBI
|
